Effects of Tamoxifen on Serum Lipid and Apolipoprotein Levels in Postmenopausal Patients with Breast Cancer

Overview

Journal Breast Cancer Res Treat

Specialty Oncology

Date 1996 Jan 1

PMID 8883969

Citations 10

Authors

M Morales

N Santana

A Soria

A Mosquera

J Ordovas

J Novoa

P Betancor

P F Valeron

R Chirino

Affiliations

Soon will be listed here.

Abstract

Serum lipids and apolipoprotein levels were measured in twenty postmenopausal women with primary breast cancer, before and three months after tamoxifen therapy (10 mg twice a day). Tamoxifen caused a significant reduction in total serum cholesterol (10%; P < 0.02), and in low-density lipoprotein cholesterol (17%; P < 0.01), and a significant 47% increase in the subclass 2 of the high density lipoprotein cholesterol (P < 0.01). In addition, tamoxifen caused a 16% increase in apolipoprotein A-I, a 12% decrease in apolipoprotein B (P < 0.05), and a 37% reduction in the serum concentration of lipoprotein (a) (P < 0.01). These results show that tamoxifen brings about an important improvement in serum lipid profile.

Citing Articles

Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies: State-of-the-Art Review.

Parashar S, Akhter N, Paplomata E, Elgendy I, Upadhyaya D, Scherrer-Crosbie M JACC CardioOncol. 2023; 5(2):159-173.

PMID: 37144116 PMC: 10152205. DOI: 10.1016/j.jaccao.2023.02.002.

Breast Cancer and the Cardiovascular Disease: A Narrative Review.

Cherukuri S, Chikatimalla R, Dasaradhan T, Koneti J, Gadde S, Kalluru R Cureus. 2022; 14(8):e27917.

PMID: 36110451 PMC: 9464354. DOI: 10.7759/cureus.27917.

Circulating lipids and breast cancer prognosis in the Malmö diet and cancer study.

Harborg S, Ahern T, Feldt M, Rosendahl A, Cronin-Fenton D, Melander O Breast Cancer Res Treat. 2021; 191(3):611-621.

PMID: 34825306 PMC: 8831289. DOI: 10.1007/s10549-021-06462-7.

Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors.

Matthews A, Peacock Hinton S, Stanway S, Lyon A, Smeeth L, Lund J Heart. 2020; 107(16):1327-1335.

PMID: 33177117 PMC: 8327412. DOI: 10.1136/heartjnl-2020-317510.

Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association.

Mehta L, Watson K, Barac A, Beckie T, Bittner V, Cruz-Flores S Circulation. 2018; 137(8):e30-e66.

PMID: 29437116 PMC: 6722327. DOI: 10.1161/CIR.0000000000000556.

References

Henderson B, Ross R, Paganini-Hill A, Mack T . Estrogen use and cardiovascular disease. Am J Obstet Gynecol. 1986; 154(6):1181-6. DOI: 10.1016/0002-9378(86)90696-4. View

FRIEDEWALD W, Levy R, Fredrickson D . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502. View

Shewmon D, Stock J, Abusamra L, Kristan M, Baker S, Heiniluoma K . Tamoxifen decreases lipoprotein (a) in patients with breast cancer. Metabolism. 1994; 43(5):531-2. DOI: 10.1016/0026-0495(94)90190-2. View

Nabulsi A, Folsom A, White A, Patsch W, Heiss G, Wu K . Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med. 1993; 328(15):1069-75. DOI: 10.1056/NEJM199304153281501. View

Olivecrona H, ERICSSON S, Berglund L, Angelin B . Increased concentrations of serum lipoprotein (a) in response to growth hormone treatment. BMJ. 1993; 306(6894):1726-7. PMC: 1678311. DOI: 10.1136/bmj.306.6894.1726-a. View

Love R, Newcomb P, Wiebe D, Surawicz T, Jordan V, Carbone P . Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst. 1990; 82(16):1327-32. DOI: 10.1093/jnci/82.16.1327. View

McDonald C, Stewart H . Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ. 1991; 303(6800):435-7. PMC: 1670561. DOI: 10.1136/bmj.303.6800.435. View

. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet. 1992; 339(8785):71-85. View

Crook D, Sidhu M, Seed M, ODonnell M, Stevenson J . Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis. 1992; 92(1):41-7. DOI: 10.1016/0021-9150(92)90008-5. View

10.

Walsh B, SCHIFF I, Rosner B, Greenberg L, Ravnikar V, Sacks F . Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991; 325(17):1196-204. DOI: 10.1056/NEJM199110243251702. View

11.

Henriksson P, Angelin B, Berglund L . Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest. 1992; 89(4):1166-71. PMC: 442975. DOI: 10.1172/JCI115699. View

12.

Fisher B, Costantino J, Redmond C, Fisher E, Wickerham D, Cronin W . Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994; 86(7):527-37. DOI: 10.1093/jnci/86.7.527. View

13.

Catherino W, Jordan V . A risk-benefit assessment of tamoxifen therapy. Drug Saf. 1993; 8(5):381-97. DOI: 10.2165/00002018-199308050-00005. View

14.

Rutqvist L, Mattsson A . Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst. 1993; 85(17):1398-406. DOI: 10.1093/jnci/85.17.1398. View

15.

Albers J, Taggart H, Haffner S, Chesnut 3rd C, Hazzard W . Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol. Biochim Biophys Acta. 1984; 795(2):293-6. DOI: 10.1016/0005-2760(84)90078-x. View

16.

Dewar J, Horobin J, Preece P, Tavendale R, Tunstall-Pedoe H, Wood R . Long term effects of tamoxifen on blood lipid values in breast cancer. BMJ. 1992; 305(6847):225-6. PMC: 1882673. DOI: 10.1136/bmj.305.6847.225. View

17.

Love R, Wiebe D, Newcomb P, Cameron L, Leventhal H, Jordan V . Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med. 1991; 115(11):860-4. DOI: 10.7326/0003-4819-115-11-860. View

18.

Kostner G, AVOGARO P, Cazzolato G, Marth E, Bittolo-Bon G, Qunici G . Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981; 38(1-2):51-61. DOI: 10.1016/0021-9150(81)90103-9. View

19.

Shewmon D, Stock J, Rosen C, Heiniluoma K, Hogue M, Morrison A . Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb. 1994; 14(10):1586-93. DOI: 10.1161/01.atv.14.10.1586. View

20.

Bagdade J, Wolter J, Subbaiah P, Ryan W . Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab. 1990; 70(4):1132-5. DOI: 10.1210/jcem-70-4-1132. View